These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17628701)

  • 1. The effect of season on cytokine expression in multiple sclerosis and healthy subjects.
    Stewart N; Taylor B; Ponsonby AL; Pittas F; van der Mei I; Woods G; Walters H
    J Neuroimmunol; 2007 Aug; 188(1-2):181-6. PubMed ID: 17628701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
    J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
    Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M
    J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis.
    Angelucci F; Mirabella M; Caggiula M; Frisullo G; Patanella K; Sancricca C; Nociti V; Tonali PA; Batocchi AP
    Peptides; 2005 Nov; 26(11):2289-93. PubMed ID: 16269354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
    J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.
    Yamaguchi KD; Ruderman DL; Croze E; Wagner TC; Velichko S; Reder AT; Salamon H
    J Neuroimmunol; 2008 Mar; 195(1-2):116-20. PubMed ID: 18279974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
    Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
    Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
    Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
    Bernal F; Elias B; Hartung HP; Kieseier BC
    Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
    Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
    Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
    Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
    Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
    J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients.
    Sternberg Z; Chadha K; Lieberman A; Hojnacki D; Drake A; Zamboni P; Rocco P; Grazioli E; Weinstock-Guttman B; Munschauer F
    J Neuroimmunol; 2008 Dec; 205(1-2):142-7. PubMed ID: 18926575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.